Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 12/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.43 |
| ▸ | GRK6 | P43250 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986346 | 0.89 | HCRTR1 (0.43) | DHODHHCRTR1HCRTR2TSPOOPRK1 | |
| SCHEMBL30775061 | 0.88 | HCRTR1 (0.53) | DHODHHCRTR1HCRTR2SLC9A1TSPO | |
| SCHEMBL269323 | 0.88 | HCRTR1 (0.53) | DHODHHCRTR1HCRTR2SLC9A1TSPO | |
| SCHEMBL268901 | 0.87 | HCRTR1 (0.39) | DHODHHCRTR1HCRTR2TSPOOPRK1 | |
| SCHEMBL2057220 | 0.85 | HCRTR1 (0.43) | DHODHHCRTR1HCRTR2SLC9A1JAK2 | |
| SCHEMBL1968436 | 0.81 | HCAR2 (0.36) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1340615 | 0.79 | HCRTR1 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL269610 | 0.79 | HPGD (0.47) | HCRTR1HCRTR2SLC9A1 | |
| SCHEMBL1341636 | 0.78 | NPC1 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL269961 | 0.77 | PIN1 (0.57) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| WO-2010004507-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | DHODH 1365/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.